Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well WORLD ALZHEIMER'S DAY came and went with nothing from the NILVAD study.
That marks the 111th time I have misread the signals from Star Tobacco, Star Scientific, Dr Mullan, Roskamp Institute, Rock Creek Pharma, or Jonnie Williams.
That leaves us with Seek's opinion that the Nilvad results will come from the British Medical Journal sometime in the next few months.
Anyone care to guess if the long delay in Nilvad Study results means good or bad news?
The Roskamp Institute was back on Facebook last evening reminding everyone that Sept is Alzheimer's Awareness Month and that Thursday Sept 21 is World Alzheimer's Day. I continue to believe that they are telegraphing "big news" to be released tomorrow! We shall soon know!
Good to hear from you again. It's been quite awhile, and I thought you may have given up on RCPIQ. Ironic though, that we have been looking at the same info, but have reached opposite conclusions.
It has been a year now since the Chapter 7 filing, and yet nothing has been done to settle the case. That led me to conclude that the filing was strictly to stop the hemorrhaging of shares, and would have had to been agreed to by all parties involved.
Also, I believe that Dr. Mullan has been sincere in his dealings as CEO of RCPI, but for whatever reason, the door has been slammed shut on the development of anatabine as a medication. I also expect that the Phase 3 NILVAD STUDY results will be positive, and will launch the possibility of Archer and Rock Creek merging, leading to the further development of the anatabine potential we have long been aware of! It sickens me to realize that anatabine could have lessened the suffering of millions, especially the aging population like myself.
The only significant negative I have ever seen about anatabine is that it was unable to make young and healthy individuals any younger or healthier. Yet many dozens of studies have presented ailments that seem ideal for anatabine treatment. Here's hoping it ends well!
In Roskamp's latest blurb on Facebook they point out that September is Alzheimer's Awareness Month and that Sept. 21st is WORLD ALZHEIMER'S DAY.
Since that falls on a Thursday, and The New England Journal of Medicine releases its weekly publication on Thursday, I nominate Sept. 21 as the day Roskamp/Archer should release the Nilvad Study results in the NEJM.
It's a perfect setup!
Bono
Right about what ? ? ?
Anyone know if the Congressionally approved, DOD funded Gulf War Illness Study using anatabine has been assigned a Trial Number?
Can't tell if the Roskamp Institute's search for Gulf War Veterans is related to GWI Study!
I'll let you two duke it out because I am looking past the accounting subject at an Archer that is the first to crack the Alzheimer's impenetrable wall. How much is that worth?
The question today is, as is has been since the Chapter 7 filing, would a successful Nilvad Phase 3 result be sufficient to rescue the Rock Creek IP via a merger of Archer and a reconstituted Rock Creek?
Roskamp and the Rock Creek IP are closer than Siamese twins. I don't believe Roskamp will give it up without a fight.
FANTASY? Perhaps! Time will tell!
You should never have been in that tunnel!
I suspect that Rock Creek creditors were part of an agreement that allowed Rock Creek to file Chapter 7 and go for nearly a year now, with no activity towards finalizing the bankruptcy.
It's still "wait and see", "wait and see", "wait and see".
For those who are not aware of it, The Roskamp Institute issued another BRAIN WAVES newsletter dated Summer 2017 Vol. 2.
Two articles caught my attention, "New grants to boost brain research" and "Medical Research: What should I believe?"
The first announced that The Roskamp Institute has received two rercent grants from the Dept. of Defense, each for 3 years duration, that total nearly $1.6 million. "The first grant will support the work of Drs. Abdullah and Crawford for a project entititled "Lipidomics for Identifying APOE4-Associated Biomarkers of AD-Related Cognitive Decline in TBI."
"The second grant will continue to fund work by Drs. Ojo and Crawford on "Novel Therapeutic Target Identification Through Analysis of Convergent AD and TBI Pathogenic Mechanisms."
The second article I latched onto was titled "Medical Research: What Should I Believe?" by Dr. Cheryl Brandi. It makes the point that there are a lot of junk medical claims out there, and that the best medical claims are most likely found in the published, peer reviewed articles in recognized and respected medical journals. I picked up on this because it has been stated that the NILVAD Phase 3 results will be peer reviewed and published by a recognized and respected medical journal. Dr. Brandi's article, then, indirectly emphasizes the validity of the soon to be released results of the Phase 3 NILVAD Study.
Lot of good stuff here!
Is this the Phase 1 results you were looking for:
https://www.streetinsider.com/Corporate+News/Rock+Creek+Pharma+%28RCPI%29+Completes+Anatabine+Citrate+Phase+1+Trial+in+U.K./10974813.html
Is this going to be another of those weeks where we hear nothing from Archer about the Nilvadipine Phase 3 results?
We are at the 8 month Anniversary of the wrap up of the study, which seems like enough time to tabulate results! Hope that doesn't mean they have run into a snag!
Similarly, we are at the 11 month Anniversary of the Chapter 7 filing! Just hope that means there is a plan in place for Rock Creek's future.
nep
Can you think of any reason why someone would do a limit sell at .0013?
There seems to be an effort to keep the price at .0013, like yesterday's trading all day at .0015, and then a small trade near the close at .0013 to make it look like a down day.
OOPS !!! Got my 90K shares @ .0013 when my ASK was at .0014. There is no fool like an old fool.
The original info was that once the Phase 3 results were tabulated they would be submitted to an appropriate medical journal for peer review and publishing. As to when results would be released all we have is one comment that said, "by Summer".
The whole game here depends on the NILVAD Phase 3 results. !!!!!!!
16,424 shares traded today, all @ .0015, except the 636 shares that went off @ .0013 @ 3: 52 P.M. How's that for "painting the tape"?
There are nearly 100K shares on the ASK @ .0016, but no takers, so no serious buyers. My 90K BID AON sits @ .0014 and am hoping it's never filled!
At one point I dropped the All Or None restriction, and a short time later my 90K showed up as the Bid. When I reinstated it, my bid disappeared.
Looks like we may have reached a trading impasse. Could it be that all persons with knowledge of the Nilvad results no longer dare to buy for fear that it will be disallowed as having been done with "inside knowledge"?
Have had a 90K "all or none" buy, in all week @ .0014, but the seller wants .0016, Hope I don't get it, as I would like to think we will go no lower.
Are we in a situation where trading was halted pending an announcement?
So far today 1 (one) share has traded. Anybody here buy it?
Anyone else noticing a stiffening up of the Bid/Ask pricing? The bid has gone from .0011 to .0013, and the Ask is at .0017.
4mark
Nilvadipine does indeed flush out plaque from the brain. However, it also reduces the production of BACE which leads to the plaques, and also is an anti-inflammatory.
Phase 3 results due any day now!
"I'm sure Nilvad removes the plaque efficiently but as they have reported without any health improvement on the brain functions !!!"
"but as they have reported without any health improvement on the brain functions !!!"
Where in heavens name did you come up with that, as there was never any such report!
On the contrary, they have reported on the discovery that all three Nilvad benefits to the brain trace back to SYK (spleen tyrosine kinase), and that taming SYK leads to the three benefits Nilvad provides to possibly taming Alzheimer's Disease.
My reaction to this video and to the much longer one where he interrupted his prepared remarks to heap much praise on Robert Roskamp and family, is that neither would have been made if the Nilvad Phase 3 results were disappointing.
I am ready for the good news, so let's get to it!
If it's any consolation, Luther, I believe we are 95% in agreement, but just not understanding each other.
For what it's worth, I believe that Dr Mullan did all that was possible under the circumstances, but the world was not ready to hear what he was saying. When the Nilvad results are in I expect that same deaf world will be stunned, and begin listening. That is when Anatabine will begin to get serious attention. Drs Mullan and Crawford are 100% in support of Anatabine, and hopefully will get the attention for it that it deserves!!!!
Since Nilvadipine has never been submitted for approval in the USA, it seems unlikely that the FDA would have had anything to say about it.
Archer has already developed ARC031, Nilvadipine without the blood pressure lowering effect. However, it seems more likely that Rosk/Arch would move ahead with seeking clearance for the current formulation because Arc031 will likely have to undergo the full trial process which will take years, and besides they have found that Nilvadipine does not lower the blood pressure of those who do not have an elevated blood pressure.
That's correct, mdropp. Nilvadipine is a 20+ year old blood pressure medication. Roskamp has invested a great deal of time, effort, and money to investigate the medical potential of both Nilvad and Anatabine, and is very unlikely to walk away from either, especially since both represent a near monopoly on their effectiveness.
That could include a combined Nilvad/Anatabine to treat Alzheimer's, although I have never heard of any attempt to test such a combination.
tensurf
Should Nilvad turn out to be the first medication that interrupts the progression of Alzheimer's to any degree, there would be an instant pent up demand for it. Archer could easily license it to one or more pharmas for hundreds of millions, IN MY OPINION! That funding could easily permit a spinning off of Archer and merger with a reincorporated Rock Creek. Would former Rock Creek shareholders be retained? My guess is "yes", because we are shareholders along with Jonnie Williams. But only time will tell us if this is just a pipe dream!
My take is that anatabine citrate will indeed have its day in the sun, but it may be without its current stockholders!
COME ON NILVADIPINE RESULTS!
SORRY! Couldn't get the link to display the news item which appears to be a DJ news release, nor would it copy and paste.
Anyway it was listed as RCPIQ "Portfolio News" on E-Trade and dated 7-21-17.
"DJ Rock Creek Pharmaceuticals Institutional Holders 2Q 2017 (RCPIQ)"
The news release purports to list the largest Institutional holders of RCPIQ, listing only 2 companies:
Marshall Wace North America LP
Ameriprise Financial Services
indicating that both sold the last of their position in the 1st qtr.
That leaves zero Institutional Holders.
As we approach the 10 month anniversary of the Chapter 7 filing, it's reasonable to assume that this is more than a common bankruptcy.
In my view all parties involved are in agreement that the solution to this situation is to await the realization of the true value of Jonnie William's IP, which I think begins with the Nilvad Phase 3 Study Results.
It's quite common in these situations for prior stockholders to get dumped, but could they dump us without dumping Jonnie?
A lot of interesting discussion, Luther, but at the risk of being repetitive I,m sticking with my preferred solution.
Roskamp announces 1st breakthrough in effort to treat Alzheimer's.
IP value of Nilvadipine to treat Alzheimer's goes through the roof.
Roskamp licenses one or more companies to produce and market Nilvadipine to treat Alzheimer's.
Roskamp spins off Archer, and Rock Creek reemerges as a functional corporation.
Archer and Rock Creek merge as equals under the name Archer Rock Creek Health, symbol ARCH, to develop a family of pharmaceuticals based on the Nilvad/Anatabine IP.
We have heard bonoinvest's opinion, and now we have heard your opinion, FOR THE FOURTH TIME!
As our overseas contributor said this should have been all wrapped-up in three months, IF THE SITUATION WERE HOPELESS!
Very first thing we need here is an encouraging report on the NILVAD Phase 3 study results. A very encouraging report would be even better!